Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccination 130

Vaccination Vaccine Immune Response Allergies 130

Scienmag

APRIL 19, 2021

A study of immune cells circulating in the blood hints the gut’s immune response to COVID-19 infection may not provide sufficient whole-body immunity from the virus Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study (..)

Immune Response 74

Immune Response Allergies Vaccination Vaccine 74

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

DECEMBER 18, 2020

ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. FRIDAY, Dec. FRIDAY, Dec. © 2020 HealthDay.

Allergies 52

Allergies Vaccination Vaccine Immune Response 52

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

XTalks

NOVEMBER 5, 2024

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. A small study from John Hopkins University has shown that a third dose of a COVID-19 vaccine could indeed help immunocompromised patients.

Vaccination 104

Vaccination Vaccine Antibody Immune Response 104

Scienmag

NOVEMBER 18, 2020

Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group Peer-reviewed / Randomised Controlled Trial / People **There will be a UK Science Media Centre briefing at 10.15am UK time on Thursday 19th November about this study. […].

Immune Response 74

Immune Response Vaccination Vaccine Trials 74

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

Scienmag

JUNE 27, 2021

Study points towards role of gut microbiome in vaccine effectiveness Credit: Image by Dr. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response.

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

Scienmag

NOVEMBER 17, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged 18-59 years recruited in China between 16 April and 5 May 2020 Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged (..)

Immune Response 70

Immune Response Vaccination Vaccine Trials 70

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccination 75

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

Scienmag

JANUARY 22, 2021

Results suggest lasting immunity after infection In a promising result for the success of vaccines against COVID-19, rhesus macaque monkeys infected with the human coronavirus SARS-CoV-2 developed protective immune responses that might be reproduced with a vaccine.

Immune Response 40

Immune Response Development Vaccination Vaccine 40

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. © 2020 HealthDay. All rights reserved. Source link.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

pharmaphorum

NOVEMBER 8, 2021

The results suggest that the REGEN-COV (casirivimab/imdevimab) antibody could play a key role in protecting people who do not mount a sufficiently strong immune response after COVID-19 vaccines, according to the company. The rate of COVID-19 vaccination was balanced between the two groups. That was down from almost $2.6

Antibody 105

Antibody Vaccination Vaccine Immune Response 105

Scienmag

JUNE 25, 2021

The latest in […].

Immune Response 75

Immune Response Vaccination Vaccine Protein 75

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. If the answer is yes, the individual should be referred to a board-certified allergist for evaluation before getting the COVID-19 vaccination, ACAAI said in a news release.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) of Beth Israel Deaconess Medical Center suggest maturation of B-cell response without further boosting. 1.1.7), Beta (B.1.351), 1.351), Gamma (P.1),

Immune Response 52

Immune Response Medicine Vaccination Vaccine 52

Scienmag

OCTOBER 15, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate was carried out in China between 29 April and 30 July 2020 and involved more than 600 healthy volunteers.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

Scienmag

FEBRUARY 19, 2021

Preclinical tests at UAB last year showed potent systemic and mucosal immune responses in mice after a single intranasal dose. The vaccine candidate was developed by Maryland-based Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to […].

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

NOVEMBER 6, 2020

New study demonstrates candidate’s potential to generate antibodies, limit viral shedding Credit: Craig Chandler, University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate (..)

Vaccination 49

Vaccination Vaccine Immune Response Genetics 49

Scienmag

SEPTEMBER 15, 2020

Scientists will study how SARS-CoV-19 hijacks the immune system and creates a ‘cytokine storm’ Credit: Sanford Burnham Prebys Medical Discovery Institute.

Immune Response 60

Immune Response Scientist Drugs Allergies 60

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. The institute also led and funded early-stage clinical research into the vaccine candidate.

Vaccination 104

Vaccination Vaccine Development Research 104

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Scienmag

JANUARY 13, 2021

Previous research suggests stress, depression, inactivity could interfere with immune response COLUMBUS, Ohio – While we wait for our turn to get vaccinated against SARS-CoV-2, we could – and probably should – use the time to make sure we bring our healthiest emotional and physical selves to the treatment, a new review of previous (..)

Vaccination 41

Vaccination Vaccine Immune Response Research 41

The Pharma Data

JULY 6, 2021

Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Global Head, Janssen Research & Development, Johnson & Johnson.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

JULY 8, 2021

Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Immune responses persisted through at least eight months.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

Scienmag

OCTOBER 1, 2020

Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Immune Response 40

Immune Response Research Allergies Vaccination 40

Scienmag

MAY 13, 2021

New study suggests COVID vaccines may still be helpful for patients with antibody deficiency disorders According to data from a cohort of adult and pediatric patients with antibody deficiencies, patients that often fail to make protective immune responses to infections and vaccinations showed robust T-cell activity and humoral immunity against SARS-CoV-2 (..)

Immune Response 53

Immune Response Antibody Protein Vaccination 53

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Nadine Rouphael, M.D.,

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Scienmag

OCTOBER 9, 2020

Findings could lay the foundation for the development of effective therapeutic and malaria vaccine strategies, which has largely been hindered by a lack of understanding of the host immune response Credit: Aissatou Diawara Abu Dhabi, UAE, October 9, 2020: The Plasmodium parasite, which transmits malaria to humans through infected mosquitos, triggers (..)

Immune Response 52

Immune Response Gene Research Vaccination 52